Delatestryl News
Market Review: Indevus Pharmaceuticals, Inc. Under Current ... - Trading Markets (press release)
... for overactive bladder, VANTAS for advanced prostate cancer, SUPPRELIN LA for central precocious puberty, and DELATESTRYL to treat male hypogonadism. ...
Indevus To Announce First Quarter Fiscal 2008 Financial Results On ... - FOXBusiness
... VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; ...
Alkermes and Indevus Announce Positive Results from Phase 2a ... - Genetic Engineering News (press release)
DELATESTRYL(R) is Indevus' registered trademark for its DELATESTRYL product. VANTAS(R) is Indevus' registered trademark for its VANTAS product. ...
Indevus Pharmaceuticals to Present at Think Equity Partners ... - CNNMoney.com
... DELATESTRYL(R) and any future products; history of operating losses and expectation of future losses; product liability and insurance uncertainties; ...
Indevus receives approvable letter from FDA for VALSTAR(R) for ... - PipelineReview.com (press release)
... VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; history of operating losses and expectation of future losses; product liability and insurance ...
Indevus Announces FDA Approval of SUPPRELIN(R)-LA - PR Newswire (press release)
The Company's marketed products include SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, and DELATESTRYL(R) to treat male ...
Indevus Announces FDA Approval of SUPPRELIN(R)-LA - Earthtimes.org
The Company's marketed products include SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, and DELATESTRYL(R) to treat male ...
Indevus to Present at the Citigroup Healthcare Conference - PR-Inside.com (Pressemitteilung)
overactive bladder, VANTAS(R) for advanced prostate cancer, and DELATESTRYL(R) to treat male hypogonadism, all of which are currently marketed, ...
Indevus to Present at the Citigroup Healthcare Conference - PharmaLive.com (press release)
The Company's approved products include SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, and DELATESTRYL(R) to treat male ...
Biotech Day In Review: MedImmune Puts Itself Up For Sale - Seeking Alpha
Indevus markets Sanctura for overactive bladder, Delatestryl for male hypgogonadism and other drugs. Valera is developing hydrogel-based implants for ...
Delatestryl RSS Feed